CTOs on the Move

RainDance Technologies

www.raindancetech.com

 
RainDance Technologies, Inc. provides microdroplet-based solutions for single molecule and single cell analysis in the life sciences industry. The company’s RainStorm technology generates various discrete droplets that can encapsulate a single molecule, single cell, or reaction. It offers RDT 1000, a solution that amplifies genomic loci and leverages the sensitivity and specificity of polymerase chain reaction methodology; and ThunderStorm System, a fully automated high-throughput targeted sequencing solution that enables researchers to determine all variation contained in any region of the genome. The company also provides research screening panels, including ASDSeq for autism spectrum disorder research; XSeq for human X-chromosome research; ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Fidelity and Health Int'l Co. Lt

Fidelity and Health Int'l Co. Lt is a Pasadena, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alpha Medical

Your doctor’s office is now online. From primary care to mental health, we’ve got you covered.

BioAbility

BioAbility is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BodyTel

BodyTel is a Reno, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem (digestive tract). Ritter Pharmaceuticals, Inc. is rapidly establishing itself as the world`s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. RP-G28, Ritter`s lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide.